Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer
Stopped early · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer. PURPOSE: This phase II trial is studying how well the combination of a proven effective allogenic whole prostate carcinoma cell (APCC) vaccine co-administered with ex vivo generated dendritic cells (DCs)(DC-APCC) extend the time to prostate cancer progression.
Key facts
- Study ID
- NCT00814892
- Run by
- Mayo Clinic
- People needed
- 2
- Starts
- 2009-01-01
- Expected to finish
- 2010-03-01
- Last updated by the study team
- 2013-11-05
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.